Preview

Научно-практическая ревматология

Расширенный поиск

Клиническое наблюдение применения тоцилизумаба при рефрактерном системном ювенильном артрите с поражением легких и синдромом активации макрофагов

https://doi.org/10.14412/1995-4484-2015-446-451

Полный текст:

Аннотация

Представлено клиническое наблюдение применения тоцилизумаба (ТЦЗ) у пациента с рефрактерным системным ювенильным артритом, особенности терапевтического ответа в реальной клинической практике, рассмотрены аспекты индивидуальной безопасности ТЦЗ при развитии синдрома активации макрофагов и проведения сопутствующей терапии

Об авторах

М. И. Каледа
ФГБНУ Научно- исследовательский институт ревматологии им. В.А. Насоновой, Москва, Россия 115522 Москва, Каширское шоссе, 34А
Россия


И. П. Никишина
ФГБНУ Научно- исследовательский институт ревматологии им. В.А. Насоновой, Москва, Россия 115522 Москва, Каширское шоссе, 34А
Россия


С. Р. Родионовская
ФГБНУ Научно- исследовательский институт ревматологии им. В.А. Насоновой, Москва, Россия 115522 Москва, Каширское шоссе, 34А
Россия


Список литературы

1. Mellins ED, Macaubas C, Grom AA. Pathogenesis of systemic juvenile idiopathic arthritis: some answers, more questions. Nat Rev Rheumatol. 2011;7(7):416–26. doi: 10.1038/nrrheum.2011.68

2. Rabinovich CE. Juvenile Rheumatoid Arthritis. Medscapee Medicine Rheumatology. Available from: http://emedicine.medscape. com/article/1007276-overview. Updated June 1, 2010. Accessed March 1, 2010.

3. Fujikawa S, Okuni M. Clinical analysis of 570 cases with juvenile rheumatoid arthritis: results of nationwide retrospective survey in Japan. Acta Paed Jpn. 1997;39(2):245–9. doi: 10.1111/j.1442- 200X.1997.tb03593.x

4. Ravelli A, Martini A. Juvenile idiopathic arthritis. Lancet. 2007;369(9563):767–78. doi: 10.1016/S0140-6736(07)60363-8

5. Алексеева ЕИ, Литвицкий ПФ. Ювенильный ревматоидный артрит. Руководство для врачей, преподавателей, научных сотрудников. Москва: ВЕДИ; 2007. 359 с. [Alekseeva EI, Litvitskii PF. Yuvenil'nyi revmatoidnyi artrit. Rukovodstvo dlya vrachei, prepodavatelei, nauchnykh sotrudnikov [Juvenile rheumatoid arthritis. Guidelines for doctors, teachers, scientists]. Moscow: VEDI; 2007. 359 p.].

6. Behrens EM, Beukelman T, Gallo L, et al. Evaluation of the presentation of systemic onset juvenile rheumatoid arthritis: data from the Pennsylvania Systemic Onset Juvenile Arthritis Registry (PASOJAR). J Rheumatol. 2008;35(2):343–8.

7. Cassidy JT. Juvenile rheumatoid arthritis. In: Cassidy JT, Petty RE, editors. Textbook of pediatric rheumatology. 4th ed. Philadelphia: W.B. Saunders Company; 2001:218–322.

8. Baum J, Alekseev LS, Brewer EJ Jr. Juvenile rheumatoid arthritis. A comparison of patients from the USSR and USA. Arthritis Rheum. 1980;23(9):977–84. doi: 10.1002/art.1780230903

9. Singh-Grewal D, Schneider R, Bayer N, Feldman BM. Predictors of disease course and remission in systemic juvenile idiopathic arthritis: significance of early clinical and laboratory features. Arthritis Rheum. 2006;54(5):1595–601. doi: 10.1002/art.21774

10. Lomater C, Gerloni V, Gattinara M, et al. Systemic onset juvenile idiopathic arthritis: a retrospective study of 80 consecutive patients followed for 10 years. J Rheumatol. 2000;27(2):491–6.

11. Grom AA, Passo M. Macrophage activation syndrome in systemic juvenile rheumatoid arthritis. J Pediatr. 1996;129:630–2. doi: 10.1016/S0022-3476(96)70140-3

12. Behrens EM, Beukelman T, Paessler M, Cron RQ. Occult macrophage activation syndrome in patients with systemic juvenile idiopathic arthritis. J Rheumatol. 2007 May; 34(5):1133–8. Epub 2007 Mar 1.

13. Davi S, Consolaro A, Guseinova D, et al. An international consensus survey of diagnostic criteria for macrophage activation syndrome in systemic juvenile idiopathic arthritis. J Rheumatol. 2011;38:764–8. doi: http://dx.doi.org/10.3899/jrheum.100996

14. Wallace CA, Levinson JE. Juvenile rheumatoid arthritis: outcome and treatment for the 1990s. Rheum Dis Clin N Am. 1991;17(4):891–905.

15. Still GF. On a form of chronic joint disease in children. 1896. Clin Orthop Relat Res. 1990 Oct;259:4–10.

16. Woo P. Systemic juvenile idiopathic arthritis: diagnosis, management, and outcome. Nat Clin Pract Rheumatol. 2006;2(1):28–34. doi: 10.1038/ncprheum0084

17. Yokota S, Miyamae T, Imagawa T, et al. Clinical study of tocilizumab in children with systemic-onset juvenile idiopathic arthritis. Clin Rev Allerg Immunol. 2005;28:231–8. doi: 10.1385/CRIAI:28:3:231

18. Yokota S, Imagawa T, Mori M, et al. Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled, withdrawal phase III trial. Lancet. 2008;371:998–1006. doi: 10.1016/S0140-6736(08)60454-7

19. Yokota S, Imagawa T, Miyamae T. Safety and efficacy of up to three years of continuous tocilizumab therapy in children with systemic- onset juvenile idiopathic arthritis [SAT0536]. Ann Rheum Dis. 2009;68 Suppl 3:715.

20. Woo P, Wilkinson N, Prieur AM, et al. Open label phase II trial of single, ascending doses of MRA in Caucasian children with severe systemic juvenile idiopathic arthritis: proof of principle of the efficacy of IL-6 receptor blockade in this type of arthritis and demonstration of prolonged clinical improvement. Arthritis Res Ther. 2005;7:R1281–8. doi: 10.1186/ar1826

21. De Benedetti F, Brunner H, Ruperto N, et al. Randomized trial of tocilizumab in systemic juvenile idiopathic arthritis. N Engl J Med. 2012;367:2385–95. doi: 10.1056/NEJMoa1112802

22. Kumar S, Kunhiraman DS, Rajam L. Application of the Yamaguchi criteria for classification of «suspected» systemic juvenile idiopathic arthritis (sJIA). Ped Rheumatol. 2012;10:40. doi: 10.1186/1546-0096-10-40

23. Reiff A. Treatment of systemic juvenile idiopathic arthritis with tocilizumab – the role of anti-interleukin-6 therapy after a decade of treatment. Biol Ther. 2012;2:1. doi: 10.1007/s13554-012-0001-6

24. Giannini EH, Ruperto N, Ravelli A, et al. Preliminary definition of improvement in juvenile arthritis. Arthritis Rheum. 1997;40:1202–9.

25. doi: 10.1002/1529-0131(199707)40:7<1202::AID-ART3>3.0.CO;2-R 25. Papadopoulou C, Kostik M, Gonzalez-Fernandez MI, et al. Delineating the role of multiple intraarticular corticosteroid injections in the management of juvenile idiopathic arthritis in the biologic era. Arthritis Care Res (Hoboken). 2013 Jul;65(7):1112–20. doi: 10.1002/acr.21947

26. Ravelli A, Magni-Manzoni S, Pistorio A, et al. Preliminary diagnostic guidelines for macrophage activation syndrome complicating systemic juvenile idiopathic arthritis. J Pediatr. 2005;146:598–604. doi: 10.1016/j.jpeds.2004.12.016

27. Isaacs JD, Harari O, Kobold U, et al. Effect of tocilizumab on haematological markers implicates interleukin-6 signalling in the anaemia of rheumatoid arthritis. Arthritis Res Ther. 2013;15(6):R204. doi: 10.1186/ar4397

28. Aoki C, Inaba Y, Choe H, et al. Discrepancy between clinical and radiological responses to tocilizumab treatment in patients with systemic-onset juvenile idiopathic arthritis. J Rheumatol. 2014;41:1171–7. doi: 10.3899/jrheum.130924


Для цитирования:


Каледа М.И., Никишина И.П., Родионовская С.Р. Клиническое наблюдение применения тоцилизумаба при рефрактерном системном ювенильном артрите с поражением легких и синдромом активации макрофагов. Научно-практическая ревматология. 2015;53(4):446-451. https://doi.org/10.14412/1995-4484-2015-446-451

For citation:


Kaleda M.I., Nikishina I.P., Rodionovskaya S.R. A CASE REPORT OF THE USE TOCILIZUMAB IN REFRACTORY SYSTEMIC JUVENILE ARTHRITIS WITH PULMONARY INVOLVEMENT AND MACROPHAGE ACTIVATION SYNDROME. Rheumatology Science and Practice. 2015;53(4):446-451. (In Russ.) https://doi.org/10.14412/1995-4484-2015-446-451

Просмотров: 412


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 1995-4484 (Print)
ISSN 1995-4492 (Online)